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Abstract 
Background: English national prospective, observational cohort study of patients continuously 
enrolled for five years in opioid substitution treatment (OST) with oral methadone and sublingual 
buprenorphine. This is a secondary outcome analysis of change in use of alcohol and other drug 
use (AOD) following identification of heroin use trajectories during OST. 
Methods: All adults admitted to community OST in 2008/09 and enrolled to 2013/14 (n=7,717). 
Data from 11 sequential, six-monthly clinical reviews were used to identify heroin and AOD use 
trajectories by multi-level Latent Class Growth Analysis. OST outcome in the sixth and seventh 
year was ‘successful completion and no re-presentation’ (SCNR) to structured treatment and was 
assessed using multi-level logistic regression. 
Results: With 'rapid decreasing' heroin use trajectory as referent, ‘continued high-level’ heroin use 
predicted ‘continued high-level’ crack cocaine use (relative risk ratio [RRR] 58.7; 95% confidence 
interval [CI] 34.2-100.5),‘continued high-level’ alcohol use (RRR 1.2; 95% CI 1.0-1.5), ‘increasing’ 
unspecified drug use (RRR 1.7; 95% CI 1.4-2.1) and less ‘high and increasing’ cannabis use (RRR 
0.5; 95% CI 0.4-0.6). 'Increasing’ crack use was negatively associated with SCNR outcome for the 
‘decreasing then increasing’ and 'gradual decreasing' heroin use groups (adjusted odds ratio 
[AOR] 0.5; 95% CI 0.3-0.9 and AOR 0.2; 95% CI 0.1-0.7, respectively). 
Conclusions: Continued high-level heroin use non-response during long-term OST is associated 
with high-level crack cocaine and alcohol use, increasing unspecified drug use, but less high and 
increasing cannabis use. Increasing use of crack cocaine is negatively associated with the 
likelihood that long-term OST is completed successfully. 
Keywords: Long-term, opioid substitution treatment; alcohol, cocaine, cannabis, trajectory 
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1. Introduction 
Opioid substitution treatment (OST), with oral methadone or sublingual buprenorphine, is the first-
line maintenance intervention for opioid use disorder (OUD). Observational studies have 
consistently reported OST to be associated with suppression of illicit opioid use (e.g. Hubbard et 
al., 2003; Mattick et al., 2014, 2009; Simpson et al., 1982; Teesson et al., 2006), a lower risk of 
opioid overdose (White et al., 2015), and reductions in crime (Russolillo et al., 2018).  
Many people with OUD present for treatment with problems associated with several substance 
classes. Darke and Hall (1995) reported that 99% of heroin users had used another drug class in 
the six-months before treatment and reported using an average of 5.2 other substances. In 
England, national statistics demonstrate that crack cocaine is the most prevalent of concurrent 
substance use disorders and has increased in those starting treatment from 42% to 54% in the 
four years to 2017/18 (Public Health England [PHE], 2018a, 2017, 2016, 2015). Crack cocaine use 
during treatment for OUD is associated with poorer suppression of illicit opioid use, worse 
acquisitive crime and psychological health outcomes and a lowered likelihood of completing 
treatment successfully (Eastwood et al., 2017; Gossop et al., 2002a; Heidebrecht et al., 2018; 
Marsden et al., 2012, 2009). Concurrent alcohol use disorder has been reported to affect around a 
third of OUD patients in treatment, although in England the prevalence is somewhat lower at 17% 
(Nolan et al., 2016; Public Health England, 2018a).  
There have been mixed findings from observational follow-up studies of change in concurrent 
alcohol and other drug use (AOD) during OUD treatment. Brecht et al. (2008) observed an 
aggregate reduction in use, while Gossop et al. (2003) reported a return to baseline levels 
following a temporary reduction, and others have reported a worsening state in a subset of non-
users at treatment admission (Gossop et al., 2002b; Weiss et al., 2015). A two-year study of heroin 
users enrolled in the Australian Treatment Outcomes Study reported that reductions in heroin use 
were not associated with increases in the use of cocaine, amphetamine, cannabis, 
benzodiazepines and other opioids (Darke et al., 2006). A longer 11-year follow-up study reported 
the use of alcohol was to be consistent across waves, ranging between 49% and 56% (Darke et 
al., 2015). Similar reductions in alcohol and other drug use has been reported in Ireland over a 3-
year follow-up period (Comiskey et al., 2009).  
Aggregated findings may, however, mask differential clinical response among sub-populations. In 
their classic 30-year study of heroin and other drug use, Grella and Lovinger (2011) reported that a 
quarter of those followed up tracked a ‘rapid decrease’ heroin use trajectory and over half of these 
reported an early increase in AOD (although specific non-opioid substance classes were not 
reported). Recently, Teesson et al. (2017) identified six heroin use trajectory groups over 11-years. 
They reported that those following the ‘no decrease’ track were more likely to have been 
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incarcerated and to be currently affected by unstable housing and to be using benzodiazepines, 
but did not examine longitudinal patterns of concurrent substance use. 
In a recent report in this journal, we identified five heroin use trajectories in a national cohort of 
patients who were continuously enrolled in OST for five years (n=7,719; Eastwood et al., 2018). 
We showed that patients following a positive treatment response trajectory towards abstinence 
were more likely to successfully complete treatment in the subsequent two-year period.  
To inform clinical practice and treatment policy, studies are needed to determine specific 
substance use change trajectories during long-term OUD treatment. Accordingly, in this related 
article, we determined the strength of evidence:  
(1) for a trajectory of patients characterised by increasing use of alcohol, cannabis, crack cocaine, 
cocaine powder, amphetamines and any unspecified drug use; 
(2) that positive and negative change in heroin use is associated with an increase in alcohol and 
other drug use; and  
(3) increased use of alcohol and other drug use predicts poor OST outcome. 
2.  Methods 
2.1  Design 
Using data from the English National Drug Treatment Monitoring System (NDTMS), this was a 
national, seven-year, prospective cohort study reported following the RECORD guidelines for 
observational research using routinely collected health data (Benchimol et al., 2015). The study 
cohort has been described in two previous reports in the journal where a detailed description of 
measures is presented (Eastwood et al., 2018, 2017). 
The present analysis concerns all patients who initiated OST between 1 April 2008 and 31 March 
2009 and were enrolled for five years, ending 31 March 2014 and followed-up to 30 September 
2016 (7,719 [14.2%] of 54,357). Following the NDTMS reporting protocol, all members of the 
cohort were either continuously enrolled in OST (i.e. they had a single unbroken episode of OST), 
or there was no more than 21 days between the end of one prescribing episode and the initiation 
of another (i.e. in the context of a transfer of a patient from one OST prescribing service to 
another).  
2.2 Measures 
2.2.1  Developmental trajectory indicators 
The Treatment Outcomes Profile (TOP; Marsden et al., 2008) is a structured, clinical interview for 
substance use disorder treatment monitoring. Using a recall period of the past 28 days, the TOP is 
completed by the clinician at the patient’s admission; then as part of a clinical review conducted 
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every six months, and at treatment completion. There were 11 TOP interviews conducted between 
Year 1 (2008/09) and Year 5 (2013/14) recording the number of days the patient reported using 
alcohol, cannabis, crack cocaine, cocaine powder, amphetamines, and any unspecified drug. The 
latter drug category is known only at the level of the treatment clinic. However, annual aggregate 
data suggest it is likely to involve benzodiazepines rather than anti-depressants, hallucinogens, 
volatile solvents, or major tranquillisers (10% prevalence versus <1%, respectively; Public Health 
England, 2018). 
For the present analysis, we used the following five heroin use trajectory classes identified by 
Eastwood et al. (2018; Figure 1)1: 
• Class 1 (n=1,617, 20.9%: ‘gradual decreasing’) 
• Class 2 (n=1,672, 21.7%: ‘decreasing then increasing’) 
• Class 3 (n=1,310, 17.0%: ‘continued low-level’) 
• Class 4 (n=1,973, 25.6%: ‘rapid decreasing’) 
• Class 5 (n=1,145, 14.9%: ‘continued high-level’) 
2.2.2  Outcome measure 
The OST outcome was the national summative measure of treatment effectiveness defined as 
successful completion and no re-presentation (SCNR) for further treatment within six months 
(Public Health England, 2018b). ‘Successful completion’ was recorded in Year 6 and Year 7 
(ending 31 March 2016) by a clinician-verified report indicating: (1) abstinence from heroin (and 
any other non-medical opioids) and cocaine; (2) remission from OUD; (3) attainment of personal 
care plan goals and (4) completion of OST. For this summative measure of OST effectiveness, we 
removed all individuals to 30 September 2016 who were re-admitted to community-based or 
prison-based treatment, or were recorded on the Office for National Statistics’ fatal drug-poisoning 
database.  
2.2.3  Baseline covariate measures 
Patient-level variables in the analysis included demographics (sex, age, ethnicity, employment, 
homelessness); social deprivation (linked to NDTMS based on the patient’s residential postcode 
district or the location of their first treatment provider in instances of missing postcode information; 
Department for Communities and Local Government, 2007); treatment admission latent drug use 
class from Eastwood et al. (2017); drug injecting status; duration of heroin use ‘career’; referral 
                                                          
1 Due to the two individuals with no AOD data, the ‘decreasing then increasing’ and ‘continued high-
level’ classes were each reduced by one individual for the present analysis.  
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route; other interventions (psychosocial; in-patient detoxification; or residential rehabilitation); and 
previous treatment for OUD. 
2.3  Statistical analysis 
Data management was done with SPSS (version 21). Given the clustering of patients within local 
treatment systems, we used multi-level Latent Class Growth Analysis (LCGA) to identify discrete, 
non-overlapping AOD use change trajectories across the five-years of OST (MPlus; version 7). 
Management of missing data (by multiple imputation) and all regression analyses was done with 
Stata (version 13).  
2.3.1 AOD use trajectories 
Sequentially, 1-class through 6-class models were fit to the data to identify unconditional trajectory 
membership. A Poisson distribution was assumed for all models and 5,000 random sets of starting 
values were used to guard against convergence on local maxima (McLachlan and Peel, 2000). 
Trajectory identification was informed by the Aikaike and Bayesian information criteria, entropy and 
the Vuong-Lo-Mendel-Ruben and bootstrapped likelihood ratio tests. A minimum class size of 5% 
of the cohort was pre-specified for utility (Borders and Booth, 2012; Willey et al., 2016).  
2.3.2 Missing data 
As LCGA is implemented by full-information maximisation likelihood, all patients with at least one 
measurement could be assigned to a latent class, but a complete case sample may yield biased 
estimates due to missing covariate data. As such, and with no evidence that missing data was not 
missing-at-random, a set of  twenty multiply imputed datasets was created using logistic 
regression, multinomial regression, and predictive mean matching for missing binary, multinomial 
or continuous data, respectively (Stata command: MI impute chained).  
2.3.3 Analysis of heroin and AOD use trajectories 
A series of multiply imputed, multivariable, multinomial logistic regressions regressed AOD use 
trajectory classes on heroin use trajectory groups, controlling for patient-level characteristics (Stata 
command: mlogit). Robust standard errors were utilised to calculate 95% confidence intervals (CI) 
to adjust for clustering of patients in each treatment system. Multiply imputed, multilevel, 
multivariable logistic regression models were used to estimate the likelihood of SCNR (Stata 
command: meqrlogit). As the likelihood of SCNR varied by heroin use trajectory, we estimated the 
association between AOD use trajectory groups and SCNR for each group. 
3.  Results 
3.1  Study cohort 
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The study cohort includes 7,719 patients for which heroin use trajectories were identified (sample 
details in Eastwood et al. 2018). These patients were recruited from all 149 local treatment 
systems in England (median 41; interquartile range [IQR] 23-71). Two patients did not complete a 
TOP assessment across all 11 assessment periods and were removed. Multilevel LCGA models 
were undertaken on 7,717 patients. A further 58 patients (0.8%) were subsequently removed as 
their original treatment records from 2008/09 were no longer available on NDTMS when assessing 
their follow-up status.   
3.2 Heroin and AOD use during five years of continuous OST 
Heroin use was reported by 85.8% of the cohort during the 28-days preceding treatment admission 
(Table 1). The most prevalent substances reported in the pre-admission month were alcohol 
(41.7%), crack cocaine (40.3%), cannabis (27.2%) and unspecified drugs (19.7%). Less than 5% 
reported using cocaine powder or an amphetamine.  
At the end of Year 5, the prevalence of heroin use fell by almost half to 43.2%. The largest 
reduction in AOD use was observed for crack cocaine (20.6%), unspecified drugs (12.0%) and 
cannabis (6.7%). The prevalence of alcohol use was reduced by 2.7%. Although cocaine powder 
and amphetamines were reduced by 2.1% and 1.5%, respectively, this represented a reduction of 
over a third (36.6%) for amphetamines and nearly a half (44.7%) for cocaine powder. Due to the 
marginal prevalence of amphetamines and cocaine powder use in the cohort, these substances 
were not included in the models.  
3.3  AOD use trajectories 
Table 2 displays the results of the multilevel LCGA models for alcohol, crack cocaine, cannabis 
and unspecified drug. For each substance, AIC, BIC, aBIC, entropy and BLRT indicators all 
pointed to six-class solutions. However, based on the model indicators, as well as the longitudinal 
separation between trajectory groups, we judged that alcohol, crack cocaine, cannabis and 
unspecified drug were best described by a more parsimonious four, five, three and three class 
model, respectively.  
Figure 2 (charts A-D) show the following trajectory classes: 
Alcohol (Figure 2A: Class 1 [n=1,323, 17.1%: ‘continued high-level]; Class 2 [n=3,810, 49.4%: 
‘continued low-level]; Class 3 [n=1,230,15.9%: ‘increasing’]; Class 4 [n=1,354, 17.6%: 
‘decreasing’]). 
Crack cocaine (Figure 2B: Class 1 [n=735, 9.5%: ‘gradual decreasing’]; Class 2 [n=924, 12.0%: 
‘increasing’]; Class 3 [n=4,576, 59.3%: ‘continued low-level’]; Class 4 [n=407, 5.3%: ‘continued 
high-level’]; Class 5 [n=1,075, 13.9%: ‘rapid decreasing’]). 
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Cannabis (Figure 2C: Class 1 [n=4,565, 59.2%: ‘continued low-level’], Class 2 [n=1,834, 23.8%: 
‘low and decreasing], Class 3 [n=1,318, 17.1%: ‘high and increasing’].  
Unspecified drug use (Figure 2D: Class 1 [n=1,047, 13.6%: ‘increasing’], Class 2 [n=5,490, 
71.1%: ‘continued low-level’], Class 3 [n=1,180, 15.3%: ‘decreasing’]. 
3.4  AOD trajectories regressed on heroin use  
The distribution of AOD trajectory groups within each of the heroin use trajectory classes is shown 
in Table 3. Relative risk ratios (RRR) and 95% confidence intervals (CI) from the multiply imputed 
multivariable multinomial regression analyses of the relationship between heroin and AOD use are 
displayed in Supplementary Tables 1-4.  
For brevity, we focused on the ‘rapid decreasing’ heroin class as the referent (Model 4, 
Supplementary Tables 1-4). Members of the ‘continued high-level’ heroin use class were:  
• more likely to be members of the ‘continued high-level’ alcohol class (21.7% vs 15.5%: 
RRR 1.24; 95% CI 1.01-1.53), and less likely to be members of the ‘decreasing’ alcohol 
use class (12.1% vs 20.4%: RRR 0.57; 95% CI 0.45-0.71);  
• more likely to members of crack cocaine ‘continued high-level’ (23.7% vs 0.8%; RRR 
58.66; 95% CI 34.23-100.54), ‘increasing’ (17.3% vs 4.5%; RRR 6.45; 95% CI 4.89-8.51), 
‘gradual decreasing’ (10.9% vs 3.4%; RRR 5.65; 95% CI 4.09-7.79) classes, were less 
likely to be members of the ‘rapid decreasing’ class (8.9% vs 22.3%; RRR 0.66; 95% CI 
0.52-0.84);  
• less likely to be members of the ‘high and increasing’ cannabis group (11.0% vs 19.2%: 
RRR 0.49; 95% CI 0.39-0.62); and  
• more likely to be members of the ‘increasing’ unspecified drug class (17.6% vs 9.7%: RRR 
1.70; 95% CI 1.36-2.12). 
3.5  Probability of membership in the heroin use trajectory group 
Table 4 shows the probability of membership in the heroin use trajectory group conditional on AOD 
classes. Among patients classified as members of ‘decreasing’ alcohol use trajectory, 10% were 
members of ‘continued high-level’ heroin non-response class, and 30% were members of the 
‘rapid decreasing’ heroin good response class.  
In the ‘gradual decreasing’ crack cocaine use class, 43% were members of the ‘gradual 
decreasing’ heroin use class, and among ‘rapid decreasing’ crack cocaine group, 41% were 
members of ‘rapid decreasing’ heroin use class. Only 1% of the ‘continued high-level’ crack 
cocaine use group were members of the ‘continued low-level’ heroin use class while 67% of this 
non-responding crack cocaine class were in the ‘continued high-level’ heroin use class. For 
cannabis, only 10% of the patients in the ‘high and increasing’ class up were members of the 
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‘continued high-level’ heroin use class. For the unspecified drug, only 14% of the continued low-
level class were members of the ‘continued high-level’ heroin class and 27% were in the ‘rapid 
decreasing’ heroin group. 
3.6  Treatment status at the end of Year 7 
At the end of Year 7, 4,615 (60.3%) were still enrolled in OST. During Year 6 and 7, 1,986 (25.9%) 
exited treatment unsuccessfully, and 1,058 (13.8%) successfully completed treatment. Among this 
group, 16.5% (n=175) were re-admitted to treatment in the next six months, five were incarcerated 
and one person died from opioid-related poisoning. The SCNR outcome was therefore achieved by 
877 of 3,044 patients discharged from OST (28.8%) .  
SCNR was most likely to be attained by the ‘rapid decreasing’ heroin class (39.7%). The 
‘continued high-level’ heroin use trajectory group was least likely to achieve the SCNR (16.2%), 
followed by the ‘decreasing then increasing’ group (19.6%). The ‘continued low-level use’ and 
‘gradual decreasing use’ groups had similar levels of SCNR (31.2% and 31.7%, respectively).   
3.7  Impact of AOD trajectory membership on outcome 
Table 5 shows the results of the multiply imputed, multivariable, multilevel logistic regression 
analyses. Within the ‘continued high-level’ heroin use class, patients with a ‘rapid decreasing’ 
crack cocaine trajectory had an increased likelihood of achieving SCNR (adjusted odds ratio [AOR] 
1.70; 95% confidence interval [CI] 1.04-2.77). Membership of the ‘increasing’ unspecified drug 
class was associated with a decreased likelihood of achieving SCNR (AOR 0.47; 95% CI 0.27-
0.81).  
Among the ‘decreasing then increasing’ heroin trajectory group, a decreased likelihood of 
achieving SCNR was associated with ‘continued high-level’ alcohol use (AOR 0.43; 95% CI 0.21-
0.88), ‘gradual decreasing’ crack use (AOR 0.42; 95% CI 0.18-0.96), ‘increasing’ crack use (AOR 
0.50; 95% CI 0.27-0.93) and ‘low and decreasing’ cannabis use (AOR 0.50; 95% CI 0.28-0.92). 
There was a decreased likelihood of achieving SCNR for patients in the ‘increasing’ crack cocaine 
class within the ‘gradual decreasing’ heroin use class (AOR 0.22; 95% CI 0.07-0.66) and an 
increased likelihood of achieving SCNR for patients in the ‘rapid decreasing’ heroin class who were 
members of the ‘low and decreasing’ cannabis class (AOR 2.39; 95% CI 1.29-4.40). 
4.  Discussion 
Over long-term continuous OST, we identified five trajectory classes for use of crack cocaine, four 
for alcohol, three for cannabis and three for unspecified drug use. In relation to our aims, each of 
these four substances contained an ‘increasing’ trajectory class. We found that the ‘rapid 
decreasing’ heroin trajectory group was less likely to be represented in both the ‘increasing’ crack 
cocaine and ‘other drug’ classes (although there was an increased likelihood of being represented 
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in the ‘high and increasing’ cannabis use group). Membership of the ‘increasing’ crack cocaine 
class was associated with a decreased likelihood of achieving the study outcome measure for two 
of the five heroin classes, while membership of the ‘increasing’ unspecified drug class was also 
associated with a decreased likelihood of achieving the outcome, at least for the ‘continued high-
level’ heroin trajectory group. 
4.1  Integration with the literature 
Similar to other group based trajectory modelling studies (Grella and Lovinger, 2011; Teesson et 
al., 2017), we identified a sub-population of OUD patients who do not report a substantial 
improvement in drug use. In our study, we demonstrate that these patients are also more likely to 
use crack cocaine and alcohol at a higher frequency than other subpopulations, and the pattern of 
alcohol and other drug use has a detectable and negative influence on eventual successful 
completion of treatment. Grella and Lovinger (2011) reported that their ‘no decrease’ group was 
more likely to be represented in the ‘late-onset increase’ of alcohol and other drug use while 
Teesson et al (2017) noted that their ‘no decrease’ trajectory group were more likely to live in 
unstable accommodation, to be imprisoned and to have injection-related health problems. Taken 
together, this seems to indicate a subpopulation for whom multiple problems emerge across 
several domains. 
The increased likelihood of ‘rapid decreasing’ and ‘continued low-level’ heroin trajectory groups 
being represented in the ‘high and increasing’ cannabis trajectory group may reflect the potential 
for use of cannabis to be associated with a pathway away from use of heroin during OST (Sifaneck 
and Kaplan, 1995). Daily cannabis use has also been associated with less severe heroin 
dependence, a lowered likelihood of daily heroin use and an increasing likelihood of never injecting 
heroin (Valdez et al., 2008). It is notable, however, that the increased use of cannabis in these two 
heroin groups did not confer any advantage in terms of completing OST successfully. If cannabis 
use does increase the likelihood of OUD recovery, it would be expected to be associated with 
treatment completion, though improved treatment outcomes have not been reported elsewhere 
(Budney et al., 2002; Epstein and Preston, 2003). While outside the scope of this paper, it is 
interesting to note the emerging evidence base of cannabinoid-opioid interactions within 
noradrenergic neural circuitry and the potential for cannabinoids to influence opioid withdrawal 
symptoms (Scavone et al., 2013). 
4.2  Strengths and limitations 
A key study strength is the national, large-scale follow-up of all individuals accessing treatment for 
opioid use disorder in England and the utilisation of the national outcomes monitoring system to 
measure change in heroin and concurrent substance use throughout patients’ long-term enrolment 
in treatment. This ‘concurrent recovery monitoring’ system (McLellan et al., 2005) is a powerful 
platform for policy makers and researchers to efficiently evaluate the effectiveness of community-
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based treatment under routine conditions. In addition, unlike other comprehensive administrative 
databases (Sahker et al., 2015; Stahler et al., 2016), the consent model supporting NDTMS 
enables linkage with subsequent treatment admissions to provide a measure of sustained recovery 
from OUD in patients exiting the treatment system.  
Several limitations are also acknowledged: first, while the frequency of use is captured by the 
Treatment Outcomes Profile, NDTMS does not capture the quantity of heroin and other drugs 
being consumed. It is possible that analysis of composite frequency by quantity metrics would yield 
different substance use trajectories, or that the ‘continued high-level’ groups do in fact demonstrate 
improvements in terms of quantity consumed. Second, NDTMS is a ‘core dataset’ and does not 
capture several covariates that may affect trajectory membership, including treatment motivation 
(Simpson and Joe, 1993), engagement (Simpson et al., 1995) and other recovery strengths 
(Gossop et al., 2002c). Third, the observational design of this study does not allow inference of 
causality. It is not possible to determine whether low-level or reducing heroin use was caused by 
increased use of cannabis (or vice versa), or whether a complex set of causal factors are involved. 
Finally, it is unfortunate that illicit benzodiazepine use is not captured by the TOP. This remains an 
important clinical issue in the treatment of OUD and is reported by a sizeable minority in the 
English treatment system.  
4.3 Clinical implications 
Findings from this study and earlier reports underscore the challenge for OST services to support 
engagement and recovery for patients with illicit OUD. If OST does not supress a patient's heroin 
use to any clinically meaningful extent, then there is a likelihood that approximately 40% will use 
alcohol or crack cocaine at a consistently high or increasing level and 1 in 7 will report increasing 
use of other unspecified drugs. Helping a patient with heroin and poly-substance use may be very 
challenging, but this should be a high priority because of immediate health needs and because the 
success of OST is diminished. Screening for AOD use is recommended at treatment admission 
and at regular clinical reviews, which can be a rapid assessment (Ali et al., 2013), and the 
assessment of other important aspects of personal and social functioning should not be overlooked 
(Marsden et al., 2014).  
If there is an unsatisfactory response to flexible dosing, it may be appropriate to suggest a change 
in medication (e.g. switching from methadone to buprenorphine), reinstate supervised 
administration (Clinical Guidelines on Drug Misuse and Dependence Update 2017 Independent 
Expert Working Group, 2017), or offer a targeted psychosocial intervention for opioids (Marsden et 
al., 2017), alcohol (Nolan et al., 2016) or cocaine (Marsden et al., 2018) from the service if there 
are resources or by referral. Although it may be discouraging that some patients continue to 
alcohol and other drugs, treatment may still offer provide important harm reduction benefits by 
reducing the risk of opioid poisoning (Cornish et al., 2010; White et al., 2015) and, taking a wider 
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societal perspective, there is an overall economic benefit-cost ratio from investing in OST (Zarkin 
et al., 2005).  
4.4  Conclusions 
This study highlights the importance of concurrent monitoring of adjunctive substance use in the 
treatment of opioid use disorder as a sizeable minority of patients either increase or maintain a 
high level of concurrent drug use and increasing drug use trajectories have a negative impact on 
positive outcome. These findings reinforce the conception of OUD as a complex and chronic 
condition. The next task for our research group is to examine the longitudinal inter-relationship 
between substance use, employment and housing. 
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Table 1. Heroin, alcohol and other drug use during five years of continuous OST (n=7,717) 
  Treatment Outcomes Profile assessment 
 Substance  Admission Year 0.5 Year 1 Year 1.5 Year 2 Year 2.5 Year 3 Year 3.5 Year 4 Year 4.5 Year 5 
Heroin             
Responses (n)  5567 5774 6409 6449 6567 6649 6670 6712 6733 6742 6746 
% using  85.8 62.7 59.2 57.0 53.3 43.6 39.6 40.6 41.9 42.6 43.2 
Mean days using (SD) *  19.5 (11.6) 7.4 (9.7) 6.0 (8.7) 5.9 (8.6) 5.4 (8.3) 4.0 (7.5) 3.5 (6.9) 3.7 (7.1) 3.6 (7.0) 3.9 (7.2) 4.0 (7.4) 
Alcohol             
Responses (n)  5496 5758 6407 6450 6569 6652 6675 6716 6737 6748 6739 
% using  41.7 43.3 43.3 42.5 41.9 42.5 42.3 41.2 40.9 40.2 39.0 
Mean days using (SD) *  5.4 (9.3) 5.2 (8.9) 5.3 (9.0) 5.2 (9.0) 5.3 (9) 5.3 (9.1) 5.5 (9.3) 5.3 (9.2) 5.4 (9.2) 5.3 (9.3) 5.3 (9.3) 
Crack             
Responses (n)  5511 5761 6401 6444 6565 6642 6667 6708 6728 6738 6740 
% using  40.3 25.1 20.4 20.3 20.3 19.6 19.2 19.2 19.1 19.2 19.7 
Mean days using (SD) *  4.5 (8.5) 2.0 (5.4) 1.5 (4.4) 1.5 (4.5) 1.5 (4.7) 1.4 (4.5) 1.5 (4.6) 1.4 (4.3) 1.4 (4.3) 1.4 (4.4) 1.4 (4.5) 
Cannabis             
Responses (n)  5463 5741 6391 6434 6555 6643 6670 6709 6721 6735 6731 
% using  27.2 24.3 23.5 22.3 21.2 22.3 22.4 22.1 21.3 21.8 20.5 
Mean days using (SD) *  3.8 (8.4) 3.5 (8.3) 3.5 (8.4) 3.4 (8.1) 3.2 (8.0) 3.4 (8.2) 3.5 (8.3) 3.5 (8.4) 3.4 (8.3) 3.5 (8.3) 3.2 (8.0) 
Unspecified drug             
Responses (n)  5395 5684 6356 6407 6554 6627 6654 6695 6713 6710 6703 
% using  19.7 9.5 8.3 7.3 7.4 6.9 7.1 7.3 7.2 7.9 7.7 
Mean days using (SD) *  3.3 (8.1) 1.7 (6.3) 1.3 (5.6) 1.2 (5.4) 1.2 (5.2) 1.1 (5.0) 1.1 (4.9) 1.0 (4.9) 1.1 (5.0) 1.1 (5.0) 1.1 (5.1) 
Cocaine powder             
Responses (n)  5438 5736 6391 6435 6559 6635 6655 6686 6700 6705 6701 
% using  4.7 3.2 2.5 2.3 2.3 2.7 2.4 2.6 2.4 2.6 2.6 
Mean days using (SD) *  0.2 (1.8) 0.1 (0.9) 0.1 (0.8) 0.1 (0.9) 0.1 (0.9) 0.1 (0.9) 0.1 (1.1) 0.1 (0.9) 0.1 (0.8) 0.1 (1.0) 0.1 (0.9) 
Amphetamines             
Responses (n)  5434 5734 6390 6434 6559 6637 6660 6692 6700 6708 6705 
% using  4.1 2.7 2.5 2.8 2.6 2.5 2.8 2.3 2.3 2.5 2.6 
Mean days using (SD) *  0.4 (2.6) 0.1 (1.4) 0.2 (1.5) 0.2 (1.6) 0.2 (1.6) 0.2 (1.7) 0.2 (1.8) 0.2 (1.5) 0.2 (1.7) 0.2 (1.8) 0.2 (1.9) 
SD = standard deviation 
* Mean days of opioid use in past 28 days
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Table 2 Unconditional multilevel latent class growth analysis of alcohol and other drug use over five years (n=7,717) 
 
Post-hoc criteria Class proportion (probability of assignment) 
Substance AIC BIC aBIC Entropy VLMR BLRT 1 2 3 4 5 6 
Alcohol 
            
Class 1 1035730.70 1035751.55 1035742.02 - - - 1.00 (1.00) 
     
Class 2 596761.37 596810.03 596787.78 0.994 <0.0001 <0.0001 0.67 (1.00) 0.33 (1.00) 
    
Class 3 518637.67 518714.13 518679.18 0.985 0.293 <0.0001 0.29 (0.99) 0.51 (1.00) 0.20 (0.99) 
   
Class 4 488513.21 488617.47 488569.81 0.980 0.135 <0.0001 0.17 (0.99) 0.49 (1.00) 0.16 (0.98) 0.18 (0.98) 
  
Class 5 466197.73 466329.81 466269.43 0.971 0.650 <0.0001 0.11 (0.97) 0.14 (0.99) 0.12 (0.98) 0.24 (0.97) 0.40 (0.99) 
 
Class 6 450851.39 451011.27 450938.18 0.967 0.200 <0.0001 0.12 (0.99) 0.11 (0.97) 0.15 (0.95) 0.09 (0.97) 0.14 (0.96) 0.40 (0.99) 
Crack cocaine 
            
Class 1 521547.29 521568.15 521558.61 - - - 1.00 (1.00) 
     
Class 2 317093.91 317142.57 317120.33 0.988 <0.0001 <0.0001 0.27 (1.00) 0.73 (1.00) 
    
Class 3 272328.31 272404.78 272369.82 0.979 0.057 <0.0001 0.10 (0.99) 0.26 (0.98) 0.64 (1.00) 
   
Class 4 252515.88 252620.15 252572.48 0.974 <0.05 <0.0001 0.15 (0.96) 0.08 (0.99) 0.63 (1.00) 0.14 (0.97) 
  
Class 5 241212.70 241344.77 241284.40 0.965 0.210 <0.0001 0.10 (0.96) 0.12 (0.96) 0.59 (0.99) 0.05 (0.98) 0.14 (0.94) 
 
Class 6 233444.82 233604.70 233531.61 0.958 0.536 <0.0001 0.05 (0.98) 0.07 (0.96) 0.14 (0.93) 0.09 (0.90) 0.56 (0.99) 0.09 (0.97) 
Cannabis 
            
Class 1 938291.53 938312.38 938302.85 - - - 1.00 (1.00) 
     
Class 2 535324.30 535372.95 535350.71 0.994 <0.0001 <0.0001 0.28 (1.00) 0.72 (1.00) 
    
Class 3 464870.58 464947.04 464912.09 0.988 0.319 <0.0001 0.59 (1.00) 0.24 (0.99) 0.17 (0.99) 
   
Class 4 432664.99 432769.26 432721.59 0.986 <0.05 <0.0001 0.13 (0.98) 0.14 (0.98) 0.60 (1.00) 0.13 (0.99) 
  
Class 5 412930.72 413062.79 413002.41 0.982 0.305 <0.0001 0.57 (1.00) 0.11 (0.98) 0.09 (0.99) 0.13 (0.97) 0.10 (0.98) 
 
Class 6 397768.05 397927.93 397854.84 0.983 0.103 <0.0001 0.56 (1.00) 0.07 (0.99) 0.08 (0.98) 0.11 (0.97) 0.11 (0.97) 0.08 (0.98) 
Unspecified drug 
            
Class 1 539800.54 539821.40 539811.86 - - - 1.00 (1.00) 
     
Class 2 348344.25 348392.91 348370.66 0.991 <0.0001 <0.0001 0.27 (0.99) 0.73 (1.00) 
    
Class 3 297333.74 297410.20 297375.25 0.986 0.217 <0.0001 0.14 (0.99) 0.71 (1.00) 0.15 (0.98) 
   
Class 4 269356.09 269460.36 269412.70 0.985 0.623 <0.0001 0.69 (1.00) 0.07 (0.99) 0.10 (0.99) 0.14 (0.97) 
  
Class 5 246710.61 246842.68 246782.31 0.981 0.409 <0.0001 0.68 (1.00) 0.09 (0.98) 0.98 (0.96) 0.99 (0.99) 0.98 (0.98) 
 
Class 6 230945.90 231105.78 231032.69 0.980 0.0187 <0.0001 0.05 (0.99) 0.68 (1.00) 0.05 (0.99) 0.10 (0.95) 0.05 (0.97) 0.06 (0.97) 
 
 AIC: Akaike Information Criterion; 
 BIC: Bayesian Information Criterion; 
 aBIC: sample-size adjusted BIC; 
 VLMR: Vuong-Lo-Mendel-Ruben test; 
 BLRT: bootstrapped likelihood ratio test.
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Table 3. Alcohol and other drug use trajectory group membership conditional on heroin use trajectory group 
 
 
 
AOD use trajectory groups 
Heroin use trajectory   
 
Total 
(n=7,659) 
Gradual decreasing 
(n=1,604) 
Decreasing then 
increasing 
(n=1,659) 
Continued low-
level 
(n=1,298) 
Rapid 
decreasing 
(n=1,957) 
Continued high-level 
(n=1,141) 
Alcohol 
      
Continued high-level 283 (17.6) 284 (17.1) 197 (15.2) e 304 (15.5) e 247 (21.7) c,d 1315 (17.2) 
Continued low-level+ 769 (47.9) 800 (48.2) 677 (52.2) 965 (49.3) 566 (49.6) 3777 (49.3) 
Increasing 247 (15.4) c 312 (18.8) c,d 184 (14.2) a,b,e 288 (14.7) b 190 (16.7) c 1221 (15.9) 
Decreasing 305 (19.0) e 263 (15.9) d,e 240 (18.5) e 400 (20.4) b,e 138 (12.1) a,b,c,d 1346 (17.6) 
Crack cocaine 
      
Gradual decreasing 317 (19.8) b,c,d,e 197 (11.9) a,c,d 25 (1.9) a,b,d,e 67 (3.4) a,b,c,e 124 (10.9) a,c,d 730 (9.5) 
Increasing 169 (10.5) b,c,d,e 368 (22.2) a,c,d 94 (7.2) a,b,e 87 (4.5) a,b,e 197 (17.3) a,c,d 915 (11.9) 
Continued low-level+ 793 (49.4) 837 (50.5) 1107 (85.3) 1352 (69.1) 448 (39.3) 4537 (59.2) 
Continued high-level 51 (3.2) c,d,e 64 (3.9) c,d,e 5 (0.4) a,b,e 15 (0.8) a,b,e 270 (23.7) a,b,c,d 405 (5.3) 
Rapid decreasing 274 (17.1) b,c,e 193 (11.6) a,c,d 67 (5.2) a,b,d,e 436 (22.3) b,c,e 102 (8.9) a,c,d 1072 (14.0) 
Cannabis 
      
Continued low-level+ 930 (58.0) 969 (58.4) 760 (58.6) 1133 (57.9) 737 (64.6) 4529 (59.1) 
Low and decreasing 391 (24.4) 433 (26.1) c,e 271 (20.9) b 448 (22.9) 279 (24.5) b 1822 (23.8) 
High and increasing 283 (17.6) e 257 (15.5) c,e 267 (20.6) b,e 376 (19.2) b ,e 125 (11.0) a,b,c,d 1308 (17.1) 
Unspecified drug 
      
Increasing 245 (15.3) c,d 248 (15.0) d 159 (12.3) a,e 189 (9.7) a,b,e 201 (17.6) c,d 1042 (13.6) 
Continued low+ 1075 (67.0) 1189 (71.7) 934 (72.0) 1464 (74.8) 781 (68.5) 5443 (71.1) 
Decreasing 284 (17.7) b,e 222 (13.4) a 205 (15.8) 304 (15.5) 159 (13.9) a 1174 (15.3) 
 
Figures presented in table are number of participants (percentages) 
+ Represents the base outcome in the from all-case, multiply imputed, multivariable multinomial logistic regression models  
a,b,c,d,e Represent significant statistical differences  when different heroin use trajectory groups are used as referent categories (c.f. Supplementary Tables 1-4) 
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Table 4 Probability of heroin use trajectory group conditional on AOD use trajectory group 
                  
AOD use trajectory 
groups 
 Heroin use trajectory group 
 
Total 
(n=7,659) 
 
Gradual 
decreasing 
(n=1,604) 
Decreasing then 
increasing 
(n=1,659) 
Continued low-
level 
(n=1,298) 
Rapid decreasing 
(n=1,957) 
Continued high-
level 
(n=1,141) 
 
Alcohol         
Continued high-level  283 (0.22) 284 (0.22) 197 (0.15) 304 (0.23) 247 (0.19)  1315 (1.00) 
Continued low-level  769 (0.20) 800 (0.21) 677 (0.18) 965 (0.26) 566 (0.15)  3777 (1.00) 
Increasing  247 (0.20) 312 (0.26) 184 (0.15) 288 (0.24) 190 (0.16)  1221 (1.00) 
Decreasing  305 (0.23) 263 (0.20) 240 (0.18) 400 (0.30) 138 (0.10)  1346 (1.00) 
Crack cocaine         
Gradual decreasing  317 (0.43) 197 (0.27) 25 (0.03) 67 (0.09) 124 (0.17)  730 (1.00) 
Increasing  169 (0.18) 368 (0.40) 94 (0.10) 87 (0.10) 197 (0.22)  915 (1.00) 
Continued low-level  793 (0.17) 837 (0.18) 1107 (0.24) 1352 (0.30) 448 (0.10)  4537 (1.00) 
Continued high-level  51 (0.13) 64 (0.16) 5 (0.01) 15 (0.04) 270 (0.67)  405 (1.00) 
Rapid decreasing  274 (0.26) 193 (0.18) 67 (0.06) 436 (0.41) 102 (0.10)  1072 (1.00) 
Cannabis         
Continued low-level  930 (0.21) 969 (0.21) 760 (0.17) 1133 (0.25) 737 (0.16)  4529 (1.00) 
Low and decreasing  391 (0.21) 433 (0.24) 271 (0.15) 448 (0.25) 279 (0.15)  1822 (1.00) 
High and increasing  283 (0.22) 257 (0.20) 267 (0.20) 376 (0.29) 125 (0.10)  1308 (1.00) 
Unspecified drug         
Increasing  245 (0.24) 248 (0.24) 159 (0.15) 189 (0.18) 201 (0.19)  1042 (1.00) 
Continued low-level  1075 (0.20) 1189 (0.22) 934 (0.17) 1464 (0.27) 781 (0.14)  5443 (1.00) 
Decreasing   284 (0.24) 222 (0.19) 205 (0.17) 304 (0.26) 159 (0.14)   1174 (1.00) 
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Table 5. Multiply imputed, multivariable, logistic regression models of SCNR outcome 
 
 
 
AOD use trajectory groups 
Heroin use trajectory  
Continued high-
level 
(n= 441; 
SCNR=16.2%) 
Decreasing then 
increasing 
(n= 649; 
SCNR=19.6%) 
Continued low-
level 
(n= 504; 
SCNR=31.2%) 
Gradual 
decreasing 
(n= 637; 
SCNR=31.7%) 
Rapid decreasing 
(n= 813; 
SCNR=39.7%) 
Alcohol 
     
Continued low-level - - - - - 
Continued high-level 0.47 (0.27,0.82) 0.43 (0.21,0.88) 0.66 (0.33,1.30) 0.75 (0.47,1.20) 1.29 (0.65,2.55) 
Increasing 0.59 (0.34,1.01) 0.97 (0.53,1.76) 0.65 (0.34,1.23) 1.31 (0.82,2.08) 0.94 (0.43,2.08) 
Decreasing 0.75 (0.46,1.22) 1.06 (0.57,1.97) 0.90 (0.51,1.59) 1.13 (0.76,1.69) 1.00 (0.42,2.39) 
Crack cocaine 
     
Continued low-level - - - - - 
Gradual decreasing 0.98 (0.60,1.61) 0.42 (0.18,0.96) 0.22 (0.02,2.04) 0.49 (0.18,1.33) 1.15 (0.43,3.04) 
Increasing 0.58 (0.29,1.16) 0.50 (0.27,0.93) 0.58 (0.23,1.44) 0.22 (0.07,0.66) 1.13 (0.53,2.41) 
Continued high-level 1.18 (0.47,2.97) 0.86 (0.29,2.55) - a - b 1.23 (0.61,2.50) 
Rapid decreasing 1.70 (1.04,2.77) 1.03 (0.54,1.97) 0.59 (0.20,1.77) 1.18 (0.81,1.71) 1.16 (0.41,3.30) 
Cannabis 
     
Continued low-level - - - - - 
Low and decreasing 0.90 (0.57,1.43) 0.50 (0.28,0.92) 1.15 (0.68,1.95) 1.31 (0.90,1.90) 2.39 (1.29,4.40) 
High and increasing 1.30 (0.80,2.12) 1.53 (0.84,2.76) 1.04 (0.59,1.83) 1.44 (0.96,2.17) 1.43 (0.59,3.42) 
Unspecified drug 
     
Continued low-level - - - - - 
Increasing 0.47 (0.27,0.81) 1.04 (0.55,1.96) 0.70 (0.34,1.43) 0.88 (0.49,1.57) 0.97 (0.47,2.00) 
Decreasing 0.84 (0.52,1.34) 1.28 (0.69,2.37) 1.02 (0.54,1.91) 0.70 (0.45,1.11) 0.92 (0.41,2.07) 
Adjusted odds ratios for baseline covariates are not shown 
a There were only 3 patients from the ‘continued low-level’ heroin trajectory group who were also in the ‘continued high-level’ crack cocaine trajectory, and these were removed from analysis. 
b There were only 5 patients from the ‘gradual decreasing’ heroin trajectory group who were also in the ‘continued high-level’ crack cocaine trajectory, and these were removed from analysis. 
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Supplementary Table 1. Multiply imputed, multivariable, multinomial logistic regression models of alcohol trajectory group membership (n=7,717) 
    Multinomial logistic regression model 
Alcohol trajectory 
group  Heroin trajectory group  
Model 1 
(Referent: 
Gradual 
decreasing 
heroin trajectory 
group) 
Model 2 
(Referent: 
Decreasing then 
increasing heroin 
trajectory group) 
Model 3 
(Referent: 
Continued low-
level heroin 
trajectory group) 
Model 4 
(Referent: Rapid 
decreasing 
heroin trajectory 
group) 
Model 5 
(Referent: 
Continued high-
level heroin 
trajectory group) 
Continued high level  Gradual decreasing  - 1.02 (0.84,1.25) 1.24 (1.00,1.54) 1.08 (0.89,1.31) 0.87 (0.70,1.07) 
  Decreasing then increasing  0.98 (0.80,1.19) - 1.21 (0.98,1.50) 1.05 (0.87,1.28) 0.85 (0.69,1.04) 
  Continued low-level  0.81 (0.65,1.00) 0.82 (0.66,1.02) - 0.87 (0.70,1.07) 0.70 (0.56,0.88) 
  Rapid decreasing  0.93 (0.76,1.12) 0.95 (0.78,1.15) 1.15 (0.93,1.42) - 0.80 (0.65,0.99) 
  Continued high-level  1.15 (0.94,1.42) 1.18 (0.96,1.45) 1.43 (1.14,1.80) 1.24 (1.01,1.53) - 
         
Increasing  Gradual decreasing  - 0.84 (0.69,1.02) 1.25 (1.00,1.56) 1.05 (0.86,1.28) 0.97 (0.78,1.21) 
  Decreasing then increasing  1.19 (0.98,1.44) - 1.48 (1.20,1.84) 1.25 (1.04,1.51) 1.15 (0.93,1.42) 
  Continued low-level  0.80 (0.64,1.00) 0.67 (0.54,0.83) - 0.84 (0.68,1.04) 0.78 (0.61,0.99) 
  Rapid decreasing  0.95 (0.78,1.16) 0.80 (0.66,0.97) 1.19 (0.96,1.47) - 0.92 (0.74,1.14) 
  Continued high-level  1.03 (0.83,1.28) 0.87 (0.70,1.07) 1.29 (1.01,1.63) 1.08 (0.87,1.34) - 
         
Decreasing  Gradual decreasing  - 1.21 (1.00,1.47) 1.09 (0.89,1.34) 0.92 (0.77,1.10) 1.63 (1.29,2.05) 
  Decreasing then increasing  0.83 (0.68,1.00) - 0.90 (0.73,1.11) 0.76 (0.63,0.91) 1.35 (1.07,1.70) 
  Continued low-level  0.92 (0.75,1.12) 1.11 (0.90,1.36) - 0.84 (0.70,1.02) 1.49 (1.17,1.90) 
  Rapid decreasing  1.09 (0.91,1.30) 1.31 (1.09,1.58) 1.19 (0.98,1.44) - 1.77 (1.41,2.21) 
    Continued high-level   0.61 (0.49,0.77) 0.74 (0.59,0.94) 0.67 (0.53,0.85) 0.57 (0.45,0.71) - 
Relative risk ratios for baseline covariates are not shown 
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Supplementary Table 2. Multiply imputed, multivariable, multinomial logistic regression models of crack cocaine trajectory group membership (n=7,717) 
    Multinomial logistic regression model 
Crack cocaine 
trajectory 
group  Heroin trajectory group  
Model 1 
(Referent: 
Gradual 
decreasing heroin 
trajectory group) 
Model 2 
(Referent: 
Decreasing then 
increasing heroin 
trajectory group) 
Model 3 (Referent: 
Continued low-level 
heroin trajectory group) 
Model 4 (Referent: 
Rapid decreasing 
heroin trajectory 
group) 
Model 5 
(Referent: 
Continued high-
level heroin 
trajectory group) 
Gradual 
decreasing  Gradual decreasing  - 1.65 (1.35,2.03) 18.59 (12.19,28.35) 8.10 (6.11,10.72) 1.43 (1.13,1.83) 
  Decreasing then increasing  0.61 (0.49,0.74) - 11.25 (7.32,17.29) 4.90 (3.65,6.57) 0.87 (0.67,1.12) 
  Continued low-level  0.05 (0.04,0.08) 0.09 (0.06,0.14) - 0.44 (0.27,0.70) 0.08 (0.05,0.12) 
  Rapid decreasing  0.12 (0.09,0.16) 0.20 (0.15,0.27) 2.30 (1.44,3.67) - 0.18 (0.13,0.24) 
  Continued high-level  0.70 (0.55,0.89) 1.15 (0.89,1.49) 12.96 (8.27,20.33) 5.65 (4.09,7.79) - 
         
Increasing  Gradual decreasing  - 0.47 (0.38,0.58) 2.47 (1.88,3.24) 3.17 (2.41,4.16) 0.49 (0.39,0.62) 
  Decreasing then increasing  2.11 (1.72,2.60) - 5.21 (4.07,6.68) 6.69 (5.21,8.59) 1.04 (0.84,1.28) 
  Continued low-level  0.41 (0.31,0.53) 0.19 (0.15,0.25) - 1.28 (0.95,1.74) 0.20 (0.15,0.26) 
  Rapid decreasing  0.32 (0.24,0.42) 0.15 (0.12,0.19) 0.78 (0.57,1.06) - 0.16 (0.12,0.20) 
  Continued high-level  2.04 (1.61,2.58) 0.96 (0.78,1.19) 5.02 (3.81,6.62) 6.45 (4.89,8.51) - 
         
Continued high 
level  Gradual decreasing  - 0.80 (0.54,1.17) 14.86 (5.88,37.58) 5.93 (3.30,10.66) 0.10 (0.07,0.14) 
  Decreasing then increasing  1.25 (0.85,1.84) - 18.63 (7.43,46.71) 7.43 (4.19,13.18) 0.13 (0.09,0.17) 
  Continued low-level  0.07 (0.03,0.17) 0.05 (0.02,0.13) - 0.40 (0.14,1.10) 0.01 (0.00,0.02) 
  Rapid decreasing  0.17 (0.09,0.30) 0.13 (0.08,0.24) 2.51 (0.91,6.95) - 0.02 (0.01,0.03) 
  Continued high-level  9.9 (7.14,13.73) 7.89 (5.82,10.7) 147.10 (59.89,361.27) 
58.66 
(34.23,100.54) - 
         
Rapid 
decreasing  Gradual decreasing  - 1.47 (1.19,1.82) 5.60 (4.20,7.45) 1.02 (0.85,1.22) 1.55 (1.20,2.00) 
  Decreasing then increasing  0.68 (0.55,0.84) - 3.80 (2.83,5.11) 0.69 (0.57,0.84) 1.05 (0.80,1.37) 
  Continued low-level  0.18 (0.13,0.24) 0.26 (0.20,0.35) - 0.18 (0.14,0.24) 0.28 (0.20,0.39) 
  Rapid decreasing  0.98 (0.82,1.17) 1.44 (1.19,1.75) 5.49 (4.18,7.21) - 1.52 (1.19,1.94) 
    Continued high-level   0.65 (0.50,0.84) 0.95 (0.73,1.24) 3.62 (2.60,5.05) 0.66 (0.52,0.84) - 
Relative risk ratios for baseline covariates are not shown 
Supplementary Table 3. Multiply imputed, multivariable, multinomial logistic regression models of cannabis trajectory group membership (n=7,717) 
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    Multinomial logistic regression model 
Cannabis trajectory 
group  Heroin trajectory group   
Model 1 
(Referent: 
Gradual 
decreasing 
heroin 
trajectory 
group) 
Model 2 
(Referent: 
Decreasing then 
increasing heroin 
trajectory group) 
Model 3 
(Referent: 
Continued low-
level heroin 
trajectory 
group) 
Model 4 
(Referent: 
Rapid 
decreasing 
heroin 
trajectory 
group) 
Model 5 
(Referent: 
Continued high-
level heroin 
trajectory 
group) 
Low and decreasing  Gradual decreasing  - 0.94 (0.79,1.10) 1.13 (0.94,1.36) 1.00 (0.85,1.17) 1.15 (0.96,1.38) 
  Decreasing then increasing  1.07 (0.91,1.26) - 1.21 (1.01,1.45) 1.07 (0.91,1.25) 1.23 (1.03,1.47) 
  Continued low-level  0.88 (0.73,1.06) 0.83 (0.69,0.99) - 0.88 (0.74,1.05) 1.02 (0.83,1.24) 
  Rapid decreasing  1.00 (0.85,1.18) 0.94 (0.80,1.10) 1.14 (0.95,1.36) - 1.15 (0.96,1.38) 
  Continued high-level  0.87 (0.72,1.04) 0.81 (0.68,0.97) 0.98 (0.80,1.20) 0.87 (0.72,1.04) - 
         
High and increasing  Gradual decreasing  - 1.17 (0.96,1.42) 0.90 (0.74,1.10) 0.88 (0.73,1.05) 1.79 (1.42,2.26) 
  Decreasing then increasing  0.86 (0.70,1.04) - 0.77 (0.63,0.94) 0.75 (0.63,0.90) 1.53 (1.21,1.94) 
  Continued low-level  1.11 (0.91,1.36) 1.30 (1.06,1.59) - 0.98 (0.81,1.18) 1.99 (1.56,2.54) 
  Rapid decreasing  1.14 (0.95,1.36) 1.33 (1.11,1.60) 1.02 (0.85,1.23) - 2.04 (1.62,2.56) 
    Continued high-level   0.56 (0.44,0.71) 0.65 (0.52,0.83) 0.50 (0.39,0.64) 0.49 (0.39,0.62) - 
Relative risk ratios for baseline covariates are not shown 
 
 
 
 
 
 
 
 
Supplementary Table 4. Multiply imputed, multivariable, multinomial logistic regression models of other drug trajectory group membership (n=7,717) 
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    Multinomial logistic regression model 
Other drug 
trajectory group  Heroin trajectory group  
Model 1 
(Referent: 
Gradual 
decreasing 
heroin 
trajectory 
group) 
Model 2 (Referent: 
Decreasing then 
increasing heroin 
trajectory group) 
Model 3 
(Referent: 
Continued low-
level heroin 
trajectory 
group) 
Model 4 
(Referent: 
Rapid 
decreasing 
heroin 
trajectory 
group) 
Model 5 
(Referent: 
Continued high-
level heroin 
trajectory 
group) 
Increasing  Gradual decreasing  - 1.06 (0.87,1.29) 1.27 (1.01,1.59) 1.58 (1.28,1.94) 0.93 (0.75,1.15) 
  Decreasing then increasing  0.94 (0.78,1.15) - 1.20 (0.96,1.49) 1.49 (1.21,1.83) 0.88 (0.71,1.08) 
  Continued low-level  0.79 (0.63,0.99) 0.84 (0.67,1.04) - 1.24 (0.99,1.57) 0.73 (0.58,0.93) 
  Rapid decreasing  0.63 (0.51,0.78) 0.67 (0.55,0.82) 0.80 (0.64,1.01) - 0.59 (0.47,0.73) 
  Continued high-level  1.08 (0.87,1.33) 1.14 (0.93,1.41) 1.37 (1.08,1.73) 1.70 (1.36,2.12) - 
         
Decreasing  Gradual decreasing  - 1.39 (1.15,1.69) 1.18 (0.96,1.45) 1.19 (0.99,1.43) 1.33 (1.07,1.65) 
  Decreasing then increasing  0.72 (0.59,0.87) - 0.85 (0.68,1.05) 0.86 (0.71,1.04) 0.95 (0.76,1.19) 
  Continued low-level  0.85 (0.69,1.04) 1.18 (0.95,1.46) - 1.01 (0.83,1.24) 1.13 (0.89,1.42) 
  Rapid decreasing  0.84 (0.70,1.01) 1.17 (0.96,1.41) 0.99 (0.81,1.21) - 1.11 (0.90,1.38) 
    Continued high-level   0.75 (0.61,0.94) 1.05 (0.84,1.31) 0.89 (0.70,1.12) 0.90 (0.73,1.11) - 
Relative risk ratios for baseline covariates are not shown 
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Figure 1. Heroin use trajectories over 5 years of continuous OST  
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Figure 2. AOD trajectories over 5 years of continuous OST 
  
A. Alcohol use trajectories  B. Crack cocaine trajectories 
 
 
C. Cannabis use trajectories D. Unspecified drug use trajectories 
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